Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dex...
April 28 2021 - 6:01AM
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a
clinical stage immuno-oncology company developing innovative
therapies for the treatment of cancer, today announced that it has
dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4
Fc), an investigational checkpoint inhibitor of the innate immune
system, in combination with the proteasome inhibitor carfilzomib
and dexamethasone.
TTI-622 is a fusion protein that is designed to
block the inhibitory activity of CD47, a molecule that is
overexpressed by a wide variety of tumors. CD47 binds to SIRPα on
macrophages and delivers a “don’t eat me” signal that inhibits the
ability of macrophages to engulf and destroy cancer cells.
Preclinical studies have shown that TTI-622 exhibits anti-myeloma
activity as a monotherapy that is enhanced when combined with
proteasome inhibitors.
“With the dosing of this patient we have begun
an exciting new phase of development for TTI-622,” commented Dr.
Ingmar Bruns, Trillium’s Chief Medical Officer. “This is the first
patient to receive TTI-622 in combination with another anti-cancer
agent, and we are eager to build upon the monotherapy activity that
we have observed in multiple hematologic cancers. More broadly,
this marks the start of a comprehensive Phase 1b/2 program that
will evaluate TTI-622 with various combination agents in five
indications and six patient settings.”
The combination of TTI-622 and carfilzomib plus
dexamethasone is being assessed as part of the ongoing, open-label
Phase 1a/1b study (NCT03530683). Approximately 30
relapsed/refractory multiple myeloma patients who have received at
least 3 prior lines of therapy which must include a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 antibody will
be enrolled. The primary endpoints are safety and overall response
rate.
“Despite the development of new therapeutics and
combinations, there remains a significant unmet medical need for
myeloma patients who relapse after earlier lines of therapy,” added
Dr. Bruns. “CD47 is overexpressed in multiple myeloma and the
overexpression is further increased in relapsed multiple myeloma.
We therefore believe that the combination of TTI-622 and
carfilzomib plus dexamethasone has strong potential to address the
unmet need and have a significant impact on the myeloma treatment
landscape, if approved.”
About Trillium Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-622 and TTI-621, target
CD47, a “don’t eat me” signal that cancer cells frequently use to
evade the immune system.
For more information
visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and applicable United States federal
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). The use of words such as "may," "will," "could",
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "seeks," "endeavor,"
"potential," "continue" or the negative of such words or other
similar expressions can be used to identify forward-looking
statements. Forward-looking statements in this press release
include express or implied statements regarding our expectation of
initiating a Phase 1b/2 program for TTI-622 in five indications and
six patient settings, and the potential for TTI-622 in combination
with carfilzomib and dexamethasone to have a significant impact on
the treatment of multiple myeloma. With respect to the
forward-looking statements contained in this press release,
Trillium has made numerous assumptions regarding, among other
things: the impact of the COVID-19 pandemic on its operations, the
effectiveness and timeliness of preclinical and clinical trials;
and the completeness, accuracy and usefulness of the data. While
Trillium considers these assumptions to be reasonable, these
assumptions are inherently subject to significant scientific,
business, economic, competitive, market and social uncertainties
and contingencies. Additionally, there are known and unknown risk
factors that could cause Trillium's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements contained in this press release. A
discussion of risks and uncertainties facing Trillium appears in
Trillium's Annual Report on Form 10-K for the year ended December
31, 2020, with the U.S. Securities Exchange Commission, each as
updated by Trillium's continuous disclosure filings, which are
available at www.sedar.com and at www.sec.gov. All
forward-looking statements herein are qualified in their entirety
by this cautionary statement, and Trillium disclaims any obligation
to revise or update any such forward-looking statements or to
publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, except as required by law.
Company Contact:Rosemary
HarrisonSVP, Corporate Development and StrategyTrillium
Therapeutics Inc. 857-412-7029
x225investors@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jul 2023 to Jul 2024